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Abstract
Background: Previous studies indicated a systemic deregulation of the pro-/antiinflammatory balance in subjects after 
6 months of a first psychotic episode. This disruption was reexamined 12 months after diagnosis to identify potential risk/
protective factors and associations with symptom severity.
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Methods: Eighty-five subjects were followed during 12 months and the determination of the same pro-/antiinflammatory 
mediators was carried out in plasma and peripheral blood mononuclear cells. Multivariate logistic regression analyses were 
used to identify risk/protective factors. Multiple linear regression models were performed to detect the change of each 
biological marker during follow-up in relation to clinical characteristics and confounding factors.
Results: This study suggests a more severe systemic pro-/antiinflammatory deregulation than in earlier pathological stages in 
first psychotic episode, because not only were intracellular components of the inflammatory response increased but also the 
majority of soluble elements. Nitrite plasma levels and cyclooxygenase-2 expression in peripheral blood mononuclear cells 
are reliable potential risk factors and 15d-prostaglandin-J2 plasma levels a protection biomarker. An interesting relationship 
exists between antipsychotic dose and the levels of prostaglandin-E2 (inverse) and 15d-prostaglandin-J2 (direct). An inverse 
relationship between the Global Assessment of Functioning scale and lipid peroxidation is also present.
Conclusions: Summing up, pro-/antiinflammatory mediators can be used as risk/protection biomarkers. The inverse 
association between oxidative/nitrosative damage and the Global Assessment of Functioning scale, and the possibility 
that one of the targets of antipsychotics could be the restoration of the pro-/antiinflammatory balance support the use of 
antiinflammatory drugs as coadjuvant to antipsychotics.
Keywords: first-episode psychosis, inflammation, biomarker, oxidative damage, risk/protective factors, antipsychotics
Introduction
The onset of psychotic illness typically occurs in late adoles-
cence or early adulthood. This first episode of psychosis (FEP) is 
suffered by about 3% of the population (Perälä et al., 2007) and its 
clinical evolution tends to chronicity. Up to 80% of the patients 
relapse during the next 5 years after a FEP, with major risk to 
become resistant to treatment. Complete remission occurs in 
only one-third of the patients (Huber et al., 2008).
The FEP population represents a unique opportunity to eval-
uate biological, clinical, and functional outcomes of psychotic 
disorders: research at the onset of illness avoids the effect of 
confounding variables (Khan et al., 2008; Bernardo et al., 2013) 
and early intervention mitigates progression and improves 
prognosis (Linszen et al., 2001).
Despite all the great efforts made involving basic and clini-
cal science, we are still far from a complete understanding of 
the pathophysiology of the disorder. Not surprisingly, <50% 
of patients respond to initial treatments (Lewis et  al., 2006). In 
the past 15 years, a great deal of interest has been focused on 
immune/inflammatory alterations and the oxidative/nitrosative 
consequences as key pathophysiological mechanisms involved 
(Müller and Schwarz, 2008; Flatow et  al., 2013). Although most 
of the scientific evidence has been found in established schizo-
phrenia, some studies indicate subtle alterations in inflamma-
tory/immune mediators and oxidative/nitrosative stress at the 
very beginning of the disease (Borovcanin et al., 2012; Martínez-
Cengotitabengoa et  al., 2012). Moreover, neuroimaging studies 
demonstrate that neuroinflammation is already present in early 
stages of schizophrenia (Pasternak et al., 2012).
In contrast, fewer studies have focused on the role of antiin-
flammatory signaling pathways, the counterbalancing mecha-
nisms that control the potentially deleterious proinflammatory 
mediators (García-Bueno et al., 2008). Recent data show a clear 
systemic misbalance in some pro-/antiinflammatory media-
tors in patients with schizophrenia (Martínez-Gras et al., 2011). 
Also, the increase of antiinflammatory cytokines (transforming 
growth factor beta and interleukin 10) seems to be a mechanism 
elicited by several antipsychotics (Meyer et al., 2011).
Recently, Flamm-PEPs, a multicenter study inside the Spanish 
national network for mental health research, presented the first 
integrated results about the imbalance of pro-/antiinflammatory 
components in peripheral blood mononuclear cells (PBMCs) in FEP 
patients (García-Bueno et al., 2013). In particular, the proinflamma-
tory pathway studied was the canonical one triggered by the acti-
vation of the nuclear transcription factor κB (NFκB) (Bierhaus et al., 
2001; Madrigal et al., 2001). NFκB activates specific DNA sequences 
in the promoter of target genes, such as those that codify for the 
inflammatory enzymes inducible nitric oxide synthase (iNOS) and 
the isoform 2 of cyclooxygenase (COX2). The overactivation of the 
enzymes produces an increase in oxidative and nitrosative media-
tors (ie, stable NO metabolites such as NO−x, prostaglandins such 
as PGE2), which can cause the depletion of endogenous antioxidant 
defences and attack membrane phospholipids, causing cell dam-
age by lipid peroxidation (García-Bueno et al., 2008). On the other 
hand, endogenous counterbalancing mechanisms are activated in 
response to inflammatory/immune stimuli, such as peroxisome 
proliferator activated receptors (PPARs). These nuclear receptors 
(mainly their gamma isoform, PPARγ; Heneka and Landreth, 2007) 
act as ligand-dependent transcription factors, decreasing the 
expression of proinflammatory genes. Interestingly, several COX-
derived products, such as the prostaglandin 15-deoxy-PGJ2 (15d-
PGJ2), act as endogenous antiinflammatory agents by targeting 
PPARγ (García-Bueno et al., 2005). Thus, the 15d-PGJ2/PPARγ path-
way is an endogenous compensatory mechanism. This pathway 
could also be pharmacologically stimulated, representing not only 
a potential biomarker but also an important new candidate thera-
peutic target in those neuropsychiatric disorders in which inflam-
mation may be playing a role.
In short, the above-cited first study of Flamm-PEPs (García-
Bueno et  al., 2013) also showed a decrease in the 15d-PGJ2/
PPARγ pathway, demonstrating a proinflammatory phenotype 
in patients during their first 6 months after diagnosis. The dis-
ruption of this physiological balance is again reexamined in 
the present follow-up study 12  months after the inclusion of 
the patients in order to (1) analyze the evolution of the balance 
described in FEP, (2) identify potential risk/protective factors, (3) 
recognize associations between pro-/antiinflammatory media-
tors and symptoms’ severity during follow-up, and finally (4) 
by means of multiple linear regression models, to analyze the 
change of every biological marker during follow-up in relation 
to clinical characteristics and confounding factors.
Methods and Materials
Subjects (see supplementary Material 1 for complete 
details)
A total of 117 FEP subjects and 106 gender-, race-, and age-
matched healthy controls were included in the baseline Flamm-
PEPs study (García-Bueno et al., 2013). From the initial sample, 85 
FEP subjects were followed during the next 6 months (maximum 
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12 months after inclusion). Baseline inclusion criteria for patients 
were: (1) age: 7 to 45 years; (2) duration of the psychotic symp-
toms: <1 year; and (3) speak Spanish correctly. The exclusion cri-
teria were: (1) mental retardation (IQ <70 together with impaired 
functioning); (2) history of traumatic head injury with loss of con-
sciousness; and (3) history of organic disease with mental reper-
cussions. Having designed a real-life patient, naturalistic study, 
substance use, or having suicidal ideation were not exclusion 
criteria (Bernardo et  al., 2013). Controls were selected from the 
same geographic areas. Inclusion criteria were: (1) same gender 
as patients; (2) similar age (±10%); (3) similar paternal socioeco-
nomic status, allowing ±1 level in the Hollingshead-Redlich scale 
(Hollingshead and Redlich, 1958); (4) no past or present psychiat-
ric disorder per DSM-IV criteria; (5) speak Spanish correctly; and 
(6) no history of psychotic disorder among first-degree relatives. 
The exclusion criteria for controls were the same as for patients.
Neither the patients nor the controls presented ongoing 
infections, fever, allergies, or other serious medical conditions 
or were receiving immunosuppressive drugs or vaccinations for 
at least 6 months prior to inclusion in the study or antiinflam-
matory-analgesics in the 2  days previous to blood extraction. 
Clinical assessment of patients and controls included a com-
plete medical history, physical examination, electrocardiogram, 
and laboratory tests (Bernardo et al., 2013).
Expert clinicians used the Spanish translation of the DSM-IV 
semistructured diagnostic interview to establish diagnosis in 
adults (First and Spitzer, 1999) and the Kiddie-Schedule for 
Affective Disorders and Schizophrenia, Present and Lifetime 
Version for subjects younger than 18 years old (Ulloa et al., 2006). 
There was a broad age of inclusion to allow the inclusion of early-
onset psychotic patients (Bernardo et  al., 2013). Medical records 
and interviews with relatives were used as other sources of infor-
mation to establish the onset of positive symptoms. The onset 
of the FEP was defined as the first week with the Positive and 
Negative Syndrome Scale (PANSS) items P1, P3, P5, P6, or G9 scoring 
≥4 (García-Bueno et al., 2013). Global Assessment of Functioning 
scale (GAF) is a numerical scale (0–100) that measures functionality 
of patients based on work and social adjustment (Hall, 1995). The 
duration of untreated psychosis (DUP) was defined as the number 
of days elapsed between this onset and the beginning of the first 
antipsychotic treatment. DUBM was defined as the number of days 
elapsed between the onset of the FEP and blood sampling.
After complete description of the study to the subjects, writ-
ten informed consent was obtained. The study was approved 
by the Ethics and Clinical Research Boards of all the hospitals 
involved in the study.
Specimen Collection and Preparation (see 
supplementary Material 1 for complete details)
Venous blood samples (10 mL) were collected between 8:00 and 
10:00 am after overnight fasting. Blood tubes were centrifuged 
(641 g x 10 minutes, 4ºC). The resultant plasma samples were 
stored at −80ºC. The rest of the sample was diluted in culture 
medium (RPMI 1640, Invitrogen), and a gradient with Ficoll-Paque 
(GE Healthcare) was used to isolate mononuclear cells by centrif-
ugation (800 g x 40 minutes, room temperature). The PBMC layer 
was aspired and resuspended in RPMI and centrifuged (1116 g x 
10 minutes, room temperature). The supernatant was removed 
and the mononuclear cell enriched pellet was stored at −80 ºC.
Biochemical Determinations in Plasma (see 
supplementary Material 1 for complete details)
Prostaglandins, the COX by-products PGE2 and 15d-PGJ2, were 
determined by enzyme immunoassay (Cayman Chemicals and 
DRG Diagnostics, respectively). Nitrites (NO−2), the final and sta-
ble product of NO, were determined by using the Griess method. 
Lipid peroxidation was determined by Thiobarbituric Acid 
Reactive Substances (TBARS) assay (Cayman Chemicals, Tallin, 
Estonia), and cotinine levels, the major degradation product of 
nicotine metabolism, were determined by enzyme immunoas-
say (Cozart).
Biochemical Determinations in PBMC (see 
supplementary Material 1 for complete details)
PBMC samples were first fractionated in cytosolic and nuclear 
extracts. Determination of proinflammatory p65 NFκB subunit 
and ant-inflammatory PPARγ respective transcriptional activi-
ties were carried out in nuclear extracts from PMBC.
NFκB Activity
Activation of NFκB occurs by enzymatic degradation of the bound 
inhibitory protein (IκBα), allowing movement from cytoplasm to 
the nucleus where they bind to consensus κB sequences in DNA. 
The presence of p65 subunit in cell nuclei is considered an index 
of activity measured with a transcription factor assay (Cayman 
Chemicals, Tallin, Estonia).
PPARγ Transcription Factor
PPARγ transcription factor activity was determined using ELISA-
based kits (Cayman Chemicals, Tallin, Estonia).
Western-Blot (WB) Analysis
Protein levels of IκBα, COX2, and iNOS were quantified by WB 
in cytosolic extracts from PBMCs. Protein levels of PPARγ were 
quantified in nuclear extracts. The housekeeping gene β-actin 
was used as loading control. Glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) was used as loading control for PPARγ (blots 
shown in the respective figures). For clarity, 2 WBs are presented 
in the figures representative of all the samples studied (in each 
different gel, n = 3 per group control or FEP).
Statistical Analysis (see supplementary Material 1 
for complete details)
Differences between baseline characteristics for patients and 
controls were assessed using chi-square, t test, or nonparametric 
Mann-Whitney U tests according to the distribution and scales of 
the variables. The effect of psychotropic medication was evaluated 
with linear regression models for each biomarker. To calculate the 
association between FEP and the level of biological markers, 5 hier-
archical logistic regression models were used in which we gradu-
ally controlled for potential confounders (age, gender, body mass 
index [BMI], cannabis use per month, and cotinine levels). Multiple 
linear regression analysis was used to analyze the change in each 
biological marker depending on the change in demographic (gen-
der, age, BMI), clinical variables (DUP, DUBM, GAF), antipsychotic 
medication (defined daily dose [DDD]), and cannabis and tobacco 
(cotinine).
Results
Demographic and Clinical Features
Table  1 presents the demographic and clinical characteristics 
of the FEP patients and the healthy control group. There were 
32 subject from the total 117 FEP subjects who did not follow 
the 6-month period of study. Because of these early drop-outs, 
there were differences in the socioeconomic status between the 
groups that were not present at baseline.
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Inflammatory and Oxidative/Nitrosative Stress 
Markers in Control and FEP Patients
Figure 1 shows mean differences (SD) in inflammatory and oxi-
dative/nitrosative stress markers in control and FEP patients. 
NFκB is a master regulator of the inflammatory and oxidative/
nitrosative status of a cell. In nuclear extracts from PMBCs, its 
activity is increased in FEP samples (supplementary Material 
2 and Figure  1a). Similarly, COX2 expression was significantly 
higher in FEP subjects, although the expression of iNOS was 
not different between groups (supplementary Material 2 and 
Figure 1b-c). At this particular stage of the disease, the plasma 
levels of PGE2, NO
−
2, and TBARS were increased in FEP (supple-
mentary Material 2 and Figure 1d-f, respectively). The numeri-
cal data for WB analysis from all subjects have been included in 
supplementary Table S3.
Table 1. Demographic and Clinical Characteristics
Characteristic Patients Baseline (N = 85) Patients Follow-up (N = 85) Controls (N = 106)
Demographic characteristics
Age, y 24.89 ± 6.26 25.21 ± 6.03 25.18 ± 6.79
Sex, n (%)
 Male 60 (70.6) — 70 (66.0)
 Female 25 (29.4) — 36 (34.0)
Psychiatric history
Socioeconomic status
 High 16 (18.8) — 14 (13.2)
 Medium-high 7 (8.2) — 17 (16.0)
 Medium 30 (35.3)* — 54 (50.9)
 Medium-low 24 (28.2) — 19 (17.9)
 Low 8 (9.4)* — 2 (1.9)
Ethnic group
 Caucasian 79 (92.9) — 96 (90.6)
 Gipsy 1 (1.2) — 0 (0)
 Maghrebian 1 (1.2) — 2 (1.9)
 Asian 1 (1.2) — 0 (0)
 Caribbean 1 (1.2) — 0 (0)
 Hispanic 2 (2.4) — 6 (5.7)
 Other 0 (0) — 2 (1.9)
Age of psychosis onset 24.37 ± 5.92 — —
DUP, d 68.58 ± 77.28 — —
Diagnosis – no. (%)
 Affective Psychosis 17 (20.0) 17 (20.0) —
 Non-affective Psychosis 68 (80.0) 68 (80.0) —
Psychopathology score
PANSS
 Total 51.72 ± 19.23 40.29 ± 23.67 —
 Positive 10.67 ± 5.38 8.01 ± 5.03 —
 Negative 14.58 ± 6.26 11.76 ± 8.15 —
 General 26.47 ± 9.75 20.52 ± 11.99 —
Young 1.45 ± 3.25 1.39 ± 3.57 —
Montgomery-Asberg 6.51 ± 6.52 6.02 ± 6.94
Overall functioning score (GAF) 68.6 ± 13.88 72.08 ± 17.23 —
Antipsychotic medication, n (%)
 Risperidone 30 (35.3) 21 (25.9) —
 Olanzapine 9 (10.6) 6 (7.4) —
 Aripiprazole 9 (10.6) 15 (18.5) —
 Paliperidone 7 (3.7) 5 (6.2) —
 Clozapine 5 (5.9) 6 (7.4) —
 Quetiapine 6 (7.1) 5 (6.2) —
 Ziprasidone 2 (2.4) 2 (2.4) —
 None 17 (8.9) 21 (25.9) —
Defined daily dose of chlorpromazine equivalents, mg 282.19 ± 253.04 298.06 ± 303.16 —
Lithium use, n (%) 8 (9.4) 7 (8.4) —
Body mass index 24.83 ± 3.81* 24.65 ± 5.73 * 23.14 ± 3.16
Cannabis use, n (%) 18 (21.18) 4 (5.1) * 14 (16.0)
Cannabis use per month, n cigarettes 4.71 ± 19.36 1.09 ± 6.37 1.15 ± 6.36
Tobacco use, n (%) 49 (57.6) 54 (65.1)* 25 (29.4)
Tobacco use per month, n cigarettes 238.9 ± 259.08 241.98 ± 254.11* 45.38 (119.31)
Cotinine, ng/mL 86.73 ± 84.46 97.27 ± 84.50* 26.28 ± 49.31
Abbreviations: DUP, duration of untreated psychosis; GAF, Global Assessment of Functioning scale.
* P < .05. Comparison between patients: follow-up and healthy controls.
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Antiinflammatory Markers in Control and FEP 
Patients
Figure 2 shows mean differences (SD) in antiinflammatory and 
oxidative/nitrosative stress markers in control and FEP patients. 
IκBα in cytosolic extracts was not decreased in patients compared 
with healthy subjects (supplementary Material 2; Figure  2a). 
However, plasma levels of the antiinflammatory 15d-PGJ2 were 
significantly lower in FEP (supplementary Material 2; Figure 2b).
Given that 15d-PGJ2 acts as an endogenous ligand for PPARγ, 
which is considered a potent antiinflammatory transcription 
factor, we analyzed its expression and transcriptional activ-
ity. WB analysis revealed lower expression of PPARγ in patients 
(supplementary Material 2; Figure  2c). Moreover, its transcrip-
tional activity was also reduced in the patient group (supple-
mentary Material 2; Figure 2d).
Multiple Logistic Regression Analysis
In the final multiple logistic regression model, 6 of 10 biologi-
cal markers studied were significantly associated with fol-
lowed FEP after controlling for all possible confounders (Table 2; 
supplementary Material 4). The resulting equation allows 
the estimation of the individual probability of FEP during a 
6-month follow-up by substituting values of the biological lev-
els and the demographic and clinical variables: log (P/1 − P) = 7.
783 + [0.005 x PGE2] + [0.017 x COX2] + [0.369 x NO-2] + [0.182 x TB
ARS] + [−0.832 x PPARγ act] + [−0.023 x 15d-PGJ2] + [0.062 x gender 
(male)] + [−0.194 x age] + [−0.070 x BMI] + [−0.014 x cannabis use per 
month] + [0.034 x cotinine] (Hosmer et al., 2013).
Among the proinflammatory markers, the highest OR 
observed was for NO−2 (OR = 1.447), meaning that for each unit 
increased of this biomarker, the risk of FEP increased by 44.7% 
[(e0.369x1 −1) x 100] after controlling for remaining biological mark-
ers and all possible confounders (P = .023). Similarly, the results 
were 20% for TBARS (not significant), 1.7% for COX2 (P = .011), and 
0.5% for PGE2 (not significant).
Among the antiinflammatory markers, the PPARγ activity 
had the lowest OR observed (OR = 0.435), meaning that the risk 
decreased by 56.5% [(e−0.832 x 1 − 1) x 100] for each unit of increased 
biomarker after controlling for remaining biological markers 
and all possible confounders, although it was not significant 
(P = .187). Similarly, the result for 15d-PGJ2 was 2.3% (P = .001).
Multiple Linear Regression Analysis
By means of multiple linear regression analysis, it is possible 
to predict the change of each biological marker from baseline 
to the follow-up point (6 to 12 months) controlling for a set of 
explanatory variables: gender, age, BMI, cannabis use, plasma 
cotinine levels, DDD of chlorpromazine equivalents, the DUP 
and the GAF scale score, and the days from diagnostic to the 
Figure 1. Mean differences (SD) in proinflammatory biomarkers between first episode of psychosis (FEP) and controls (univariate analysis). (a) Nuclear transcription 
factor κB (NFκB) activity in peripheral blood mononuclear cell (PBMC) nuclear extracts from FEP patients (n = 85) and controls (n = 35). (b) Western-blot analysis of 
isoform 2 of cyclooxygenase (COX2) protein (patients n = 85, controls, n = 88); (c) Inducible nitric oxide synthase (iNOS) in PBMC cytosolic extracts from FEP patients 
(n = 85) and controls (n = 88); and (d) PGE2 (patients, n = 85; controls, n = 104). (e) Plasma levels of nitrites (NO
−
2) (patients, n = 85; controls, n = 61). (f) Thiobarbituric acid 
reactive substances (TBARS) (patients, n = 85; controls, n = 104). AU, arbitrary units. Two-tailed nonparametric Mann-Whitney U test was used. ° represents an atypical 
value and * an extreme value.
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blood sampling for basal values (DUBM). Four (PGE2, COX2, NO
−
2, 
and TBARS) of the 6 proinflammatory and oxidative/nitrosative 
biological markers studied and 2 (15dPGJ2 and PPARγ activity) 
of the 4 antiinflammatory markers studied were significantly 
associated with some of the explanatory variables (Table 3).
Inflammatory and Oxidative/Nitrosative Stress 
Markers
The increased plasma levels of PGE2 from baseline to follow-
up appeared negatively related to DDD (for each DDD unit 
Figure 2. Mean differences (SD) on antiinflammatory biomarkers. (a) Western-blot analysis of bound inhibitory protein (IκBα) in peripheral blood mononuclear cell 
(PBMC) cytosolic extracts (patients, n = 85; controls, n = 88); (b) Plasma levels of prostaglandin 15d-PGJ2 (patients, n = 85; controls, n = 104). (c) Western-blot analysis of 
peroxisome proliferator activated receptor γ (PPARγ; patients, n = 85; controls, n = 16). (d) Transcriptional activity of PPARγ (patients, n = 85; controls, n = 87) in PBMC 
nuclear extracts. AU, arbitrary units. Two-tailed t test was assessed for PPARγ protein levels, and for the rest of variables, 2-tailed nonparametric Mann-Whitney U test 
was used. ° represents an atypical value and * an extreme value.
Table 2. Multivariate Logistic Regression Analysis
B SE Wald OR CI 95% P
PGE2 0.005 0.002 3.721 1.005 1.000–1.009 .054
COX2 0.017 0.007 6.509 1.017 1.004–1.031 .011
NO-2 0.369 0.163 5.137 1.447 1.051–1.991 .023
TBARS 0.182 0.162 1.269 1.200 0.874–1.649 .260
PPARγ act −0.832 0.631 1.741 0.435 0.126–1.498 .187
15d-PGJ2 −0.023 0.007 10.099 0.977 0.963–0.991 .001
Abbreviations: B, median; COX-2: cyclooxygenase 2; CI, confidence interval; NO-2, nitrites; OR, odds ratio; PGE2, prostaglandin E2; PPARg act, peroxisome proliferator 
activated receptors activity; SE, standard error; TBARS, thiobarbituric acid reactive substances; 15d-PGJ2, prostaglandin 15-deoxy-PGJ2.
Association between FEP and level of biomarker. All the biomarkers were analyzed together and adjusted for age, gender, body mass index, cannabis use per month, 
and cotinine level. The bold values in the table represent the values reaching statistical significance (P < .05).
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increased during this period, PGE2 will decrease 0.733 units 
during follow-up, once controlling the effect of the increase 
in the other explanatory variables; Table 4). Also, PGE2 will 
decrease 3.387 units for each increase in 1 unit of cotinine 
plasma levels and will increase 0.714 units DUBM. COX2 
expression was also related to cotinine: it will increase 0.672 
units for each unit of cotinine level increased from basal 
to follow-up. The increase in nitrite levels also appeared 
related to the explanatory variables chosen: NO−2 increased 
by 7.451 units more in female patients than in male patients 
(Kleinbaum et al., 2008).
The increase of TBARS plasma levels from basal to follow-
up, the final marker of systemic oxidative/nitrosative stress, also 
appeared related to clinical status: for each unit of GAF scale 
increase, TBARS decreases 0.12 units. Finally, for DUBM, TBARS 
will increase 0.005 units.
Antiinflammatory Markers
Plasma levels of 15d-PGJ2 from baseline to the follow-up were pos-
itively related to DDD (for each DDD unit during this period, 15d-
PGJ2 will increase 0.333 units during follow-up, once controlling 
the effect of the increase in the other explanatory variables; Table 
4). Finally, the activity of PPARγ will decrease 0.033 units for each 
point in GAF score and increases 0.75 units for each year of age.
Discussion
In this follow-up study, we have strengthened the evidence of 
systemic inflammatory alterations in FEP patients. Previously, 
with this same cohort of patients, we described phenotypi-
cal differences in proinflammatory mediators at the cellular 
machinery level in PBMCs, but the resultant soluble elements 
were not significantly altered (García-Bueno et  al., 2013). 
However, 6 months later, some of the soluble elements analyzed 
already appeared significantly altered (PGE2, TBARS, 15d-PGJ2), 
suggesting the existence of a deeper deregulation of the pro/
antiinflammatory balance (supplementary Table S5).
The multivariate logistic regression analysis identified the 
plasma levels of the marker of oxidative/nitrosative damage 
NO−2 and the COX2 expression in PBMCs as the most reliable 
potential risk factors. Also, plasma levels of the antiinflamma-
tory 15d-PGJ2 might be used as a potential protection factor 
for FEP.
The current longitudinal approach allowed the analysis of 
the changes of every biological marker between 6 and 12 months 
after the inclusion of the patients in relation to the changes 
of clinical characteristics and confounding factors. Especially 
remarkable are the associations found between the antipsy-
chotic dose and the change in the plasma levels of PGE2 (inverse) 
and 15d-PGJ2 (direct). Indeed, these results suggest that one of 
the therapeutic mechanisms of antipsychotics may be the res-
toration of the pro-/antiinflammatory balance disrupted in FEP. 
It is worth noting that 25.9% of the FEP patients recruited here 
were receiving medication with risperidone, an atypical antipsy-
chotic drug that normalizes increased inflammatory mediators 
(cytokines and inflammatory PGs) (Sugino et  al., 2009; Adkins 
et al., 2012) and restores antiinflammatory pathways in murine 
models of neuroinflammation (MacDowell et  al., 2013). In our 
conditions, the increase of inflammation during follow-up can 
be due to the fact that antipsychotics are not able to completely 
reverse the inflammation associated with the disease, and this 
circumstance could justify the potential use of antiinflamma-
tory drugs as coadjuvant to antipsychotics for the treatment of 
the psychotic disease (Sommer et al., 2012).
Other results deserving attention are the opposite relation-
ships found between cotinine levels and COX-2 protein expres-
sion in PBMCs and PGE2 plasma levels. Nicotine effects on 
the cyclooxygenase pathway in an inflammatory context are 
complex and sometimes contradictory, depending of the nico-
tine levels reached, subtype of receptor activated, the route of 
administration of nicotine, and whether there is a subjacent 
pathological state (Piao et al., 2009; Gonçalves et al., 2011; Hurley 
and Tizabi, 2013). Our paradoxical results need to be further 
explored to analyze the effects of nicotine on the antiinflam-
matory α7 nicotinic acetylcholine receptor (Hurst et al., 2013) or 
on the expression and enzymatic activity of tissue-specific PGE2 
synthases, such as microsomal-PGE-synthase-1. Our results 
support the idea that cigarette smoking is a potent confound-
ing factor to control for when the inflammation/innate immune 
system is studied.
Regarding other potential confounding factors, the results 
described here suggest that the alterations in the pro-/antiin-
flammatory balance in FEP patients are not related to changes 
in BMI in both time-points studied (see supplemental Table 
S6). In addition, NO−2 plasma levels increased more in female 
than in male patient subjects between both time points stud-
ied, age was directly related to PPARγ activity, and cannabis use 
Table 3. Differences (Mean ± SD) in the Biomarker Levels between Baseline (6 Months After Diagnosis) and 1-Year Follow-Up Patients
Marker Patients Baseline (N = 85) Patients Follow-Up (N = 85) Statistics P
iNOS -WBc- 131.44 ± 51.43 109.05 ± 52.89 Z = −2.47 .013
COX2 -WBc- 161.08 ± 164.82 230.60 ± 169.86 Z = −3.13 .002
NFκB -act- 12.13 ± 23.75 5.52 ± 2.75 Z = −0.20 .845
PGE2 -sol- 522.29 ± 770.33 870.02 ± 741.96 Z = −4.58 <.001
NO-2 -sol- 14.94 ± 6.20 17.61 ± 7.34 Z = −1.88 .060
TBARS -sol- 3.65 ± 3.81 4.50 ± 1.75 Z = −3.69 <.001
IκBα -WBc- 86.36 ± 49.97 104.21 ± 82.09 Z = −0.73 .468
15d-PGJ2 -sol- 571.25 ± 154.15 408.89 ± 150.69 Z = −5.72 <.001
PPARγ -WBn- 79.45 ± 33.51 55.94 ± 49.09 Z = −2.35 .019
PPARγ -act- 1.29 ± 0.93 1.09 ± 0.55 Z = −1.11 .267
Abbreviations: act, activity assay in nuclear extracts; sol: plasma levels of soluble compounds; COX-2, cyclooxygenase 2; IkBa, inhibitor of the NFkB alpha; iNOS, in-
ducible nitric oxide synthase; NFκB, nuclear transcription factor κB; NO-2, nitrites; PGE2, prostaglandin E2; PPARg, peroxisome proliferator activated receptor gamma; 
TBARS, thiobarbituric acid reactive substances; 15d-PGJ2, prostaglandin 15-deoxy-PGJ2.
Nonparametric Wilcoxon signed-rank test was used. The bold values in the table represent the values reaching statistical significance (P < .05). Analyses carried out in 
WB: protein expression, determined by western blot in PBMC (WBc: in cytoplasmatic fraction; WBn: in nuclear fraction). See Methods for details.
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per month was inversely related to NO−2 plasma levels. Further 
studies are needed to corroborate whether these relationships 
are particular for PEPs or can be extended to other states of psy-
chotic disease. From a clinical point of view, the inverse relation-
ship found between the GAF scale and TBARS plasma levels is 
particularly relevant and provides scientific evidence of a direct 
role for oxidative/nitrosative stress cellular damage in the gen-
eral symptomatology of FEP and possibly in other disorders with 
psychotic symptoms. In a comparable cohort of patients, it has 
been reported that cognitive deficits are related to oxidative 
stress (Martínez-Cengotitabengoa et al., 2012).
As previously described, the longitudinal design of this study 
allowed to analyze the evolution of the inflammatory response 
taking place in FEP patients. The comparison of the data 
obtained in the 2 selected time-points illustrates the complex 
and continuous dynamic changes of the inflammatory response 
in the natural course of incipient psychosis. This complexity 
might be one of the causes of controversy regarding the specific 
role of inflammatory mediators in the pathophysiology of the 
different types of psychotic disorders (Meyer et al., 2011) and the 
difficulties in the design and proper use of treatment strategies 
based on classical antiinflammatory drugs, producing in most 
cases only relatively modest improvements in clinical symp-
toms in the early stage of schizophrenia (Sommer et al., 2012).
The results of the multivariate analysis show potential risk/
protective factors common in both baseline and follow-up visits. 
This is the case of COX2 protein levels in PBMCs as a risk fac-
tor and 15d-PGJ2 plasma levels as a putative protection factor. 
However, other plausible biomarkers have lost their validity (ie, 
IκBα). These results illustrate how one biomarker could be use-
ful in a limited phase of the natural course of the disease (sta-
tus biomarker), but others are more general for all the phases 
of the disease (trait biomarker), as has been shown for specific 
cytokines (Miller et al., 2011).
The reformulation of the traditional conception of the psy-
chotic illness, being now considered as a heterogeneous dis-
order with multisystemic impact in addition to its psychiatric 
expression (Kirkpatrick, 2009), is clearly supported by these data. 
Recent studies compared the same immune biomarkers (eg, 
cytokines such as IFNγ) in plasma and postmortem brain tissue 
from control and subjects with schizophrenia and found simi-
lar alterations in both compartments, validating the concept 
that schizophrenia can be studied through systemic biomarkers 
(Harris et  al., 2012). A  recent review suggested a link between 
peripheral inflammatory/immune processes and MRI-detected 
anomalies in the brain (Frodl and Amico, 2014), and studies 
in postmortem brain tissue from subjects with schizophrenia 
showed increased levels of some of the pro-/antiinflammatory 
and oxidative/nitrosative stress markers studied here (NFκB, 
COX2, TBARS) (Rao et al., 2013). Our data might serve to eluci-
date whether the alterations of these inflammatory risk/protec-
tion biomarkers could have etiological relevance and not only 
utility for diagnosis and monitoring the evolution of the disease 
(Bergink et al., 2013).
The present study identifies vulnerability conditions related 
to PBMC pro-/antiinflammatory pathways in FEP patients. One 
special feature of the study is that it includes a wide spectrum 
of biochemical markers in both PBMCs and plasma, allowing 
to establish in-depth relationships between multiple compo-
nents of the signalling pathways. In addition, we have used 
the DUBM variable that enhances the accuracy of the values 
obtained in each biomarker. Thus, this variable is especially rel-
evant in the particular case of the proinflammatory/oxidative 
stress biomarkers PGE2 and TBARS, which significantly increase 
depending on the days between diagnosis and the moment of 
blood extraction. Additional studies that analyze inflammatory/
immune biomarkers in psychiatric disease should take into 
account and control for this variable.
Limitations
The present results may also explain one possible limitation 
reported in our first study (García-Bueno et al., 2013) about the 
role of stress in the observed changes: stress exposure could 
be one of the factors implicated in the onset of FEP (Holtzman 
et  al., 2013), and stress could contribute to the observed shift 
towards enhanced pro- vs antiinflammatory signalling (García-
Bueno et al., 2005). However, current results indicate a clear evo-
lution after 1 year (not only were intracellular components of 
the inflammatory response increased, but also the majority of 
resultant proinflammatory soluble elements and the oxidative/
nitrosative stress markers). Also, the deregulation of the balance 
is permanent in chronic schizophrenic inpatients with a 13-year 
history of psychosis (Martínez-Gras et al., 2011). This evolution 
suggests that the inflammatory process is not merely due to 
acute stress exposure in the beginning of FEP.
Control subjects were not followed 6 months after baseline 
as patients were, and this could be considered a major limita-
tion. When this study was designed, our hypothesis was that the 
pro-/antiinflammatory mediators analyzed did not significantly 
Table 4. Multiple Linear Regression Analysis
PGE2 COX2 NO
-
2 TBARS 15d-PGJ2 PPARγ act.
ß P ß P ß P ß P ß P ß P
Gender (ref. female) −45.635 .805 −37.395 .426 7.451 .015 1.793 .083 −31.095 .625 −0.179 .632
Age −5.010 .759 −0.462 .915 −0.042 .870 0.108 .232 −11.284 .052 0.075 .048
Body mass index −1.898 .932 5.596 .281 −0.038 .903 −0.217 .073 2.463 .743 −0.141 .093
Antipsychotic DDD −0.733 .028 0.148 .085 0.006 .236 −0.001 .604 0.333 .006 0.000 .888
DUP 1.020 .462 0.187 .578 0.019 .355 −0.013 .080 −0.025 .957 0.003 .274
GAF −3.401 .660 2.490 .206 0.122 .263 −0.120 .005 0.783 .763 −0.033 .024
Cannabis use per month −0.619 .890 −1.296 .215 −0.190 .008 0.015 .531 0.994 .510 −0.003 .714
Cotinine plasma levels −3.387 .007 0.672 .046 0.001 .955 0.001 .927 0.503 .225 0.002 .343
DUBM 0.714 .017 −0.047 .500 0.001 .837 0.005 .002 −0.057 .563 0.000 .555
Abbreviations: ß, linear regression coefficient; BMI, body mass index; DDD, defined daily dose of antipsychotic chlorpromazine equivalents; DUBM, number of days 
elapsed between the onset of the FEP and blood samplings; DUP, duration of untreated psychosis; GAF, Global Assessment of Functioning scale.
Change of each biological marker (from baseline to the follow-up point) depending on demographic and clinical variables. The bold values in the table represents the 
values reaching statistical significance (P < .05).
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change in 6 months in control subjects. However, this possibility 
exists, and the interpretation of the results obtained 6 months 
after baseline with regards to control subjects should be done 
with caution. The main objective of the experimental design 
made was to study the intra-subject evolution of the disease 
between both time points.
It is worth noting that 75% of the FEP patients included in our 
study were under atypical antipsychotic treatment, and there is 
increasing evidence on the potential antiinflammatory effects of 
antipsychotics (Sugino et al., 2009; Miller et al., 2011; MacDowell 
et al., 2013). Nevertheless, we tried to control the possible con-
founding effect of antipsychotic treatment through a multiple 
linear regression analysis.
In addition, each antipsychotic group and lithium have very 
different impacts on metabolic signalling (weight gain), and with 
the approximation made with the chlorpromazine equivalents, 
their differential profile could be lost. To resolve this issue, we 
analyzed if there are differences in weight gain between basal 
and follow-up time points studied and between the different 
antipsychotic groups and lithium, respectively (supplementary 
Tables S6-8) and there were no significant differences.
Finally, it would be necessary to determine if the peripheral 
changes found in inflammatory-related molecules in FEP sub-
jects could also take place at a central level.
Conclusion
In conclusion, this follow-up study corroborates the existence 
of a deregulated systemic pro-/antiinflammatory balance in FEP, 
which becomes more severe during the initial 1 year after the 
diagnosis. The multivariate analysis applied shows potential 
risk/protective factors in both time points studied (COX-2 pro-
tein levels in PBMCs and 15d-PGJ2 plasma levels) that can be con-
sidered trait markers and other specific state biomarkers (initial: 
IκBα; 1-year evolution: NO−2 and TBARS). Striking results come 
from the multiple linear regression approach, which shows how 
one of the targets of antipsychotic treatment may be the resto-
ration of the inflammatory balance. Finally, from a clinical point 
of view, the inverse relationship found between the final prod-
uct of oxidative/nitrosative cellular damage TBARS and the GAF 
scale is especially relevant in order to justify the development 
of antioxidant/antiinflammatory treatment strategies not only 
for established schizophrenia but also for earlier stages of a psy-
chotic disorder.
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